Skip to content

Precision Bio CAR T candidate Fast Track’d for multiple myeloma

September 9, 2020

The FDA designates Precision BioSciences’ (NASDAQ:DTIL) PBCAR269A, a CAR T cell therapy, for Fast Track review for the treatment of relapsed/refractory multiple myeloma (MM).

The candidate is currently being evaluated in an open-label, parallel assignment, single-dose, dose-escalation and dose-expansion Phase 1/2a clinical trial in MM patients.

Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: